Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $17.33 Average PT from Analysts

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has earned a consensus recommendation of “Buy” from the six brokerages that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $17.33.

TNYA has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a research note on Monday, February 3rd. Chardan Capital reiterated a “buy” rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a research note on Wednesday, December 18th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TNYA. Synovus Financial Corp bought a new position in Tenaya Therapeutics during the 3rd quarter worth $28,000. Woodline Partners LP bought a new position in shares of Tenaya Therapeutics in the 4th quarter worth about $28,000. Commerce Bank bought a new position in shares of Tenaya Therapeutics in the 4th quarter worth about $29,000. Mariner LLC bought a new position in shares of Tenaya Therapeutics in the 4th quarter worth about $30,000. Finally, Ground Swell Capital LLC bought a new position in shares of Tenaya Therapeutics in the 4th quarter worth about $32,000. 90.54% of the stock is owned by institutional investors.

Tenaya Therapeutics Stock Performance

Shares of TNYA stock opened at $0.47 on Tuesday. The stock’s fifty day moving average price is $1.17 and its two-hundred day moving average price is $1.92. The company has a market cap of $37.23 million, a PE ratio of -0.33 and a beta of 2.84. Tenaya Therapeutics has a fifty-two week low of $0.39 and a fifty-two week high of $6.78.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.